Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent progress in tumour vaccine development.

I Caroline Le Poole1, Hemamalini Bommiasamy, W Martin Kast

  • 1Oncology Institute, Loyola University Medical Center, 2160 S. 1st Ave, Maywood, IL 60153, USA. ilepool@lumc.edu

Expert Opinion on Investigational Drugs
|June 5, 2003
PubMed
Summary

Cancer immunotherapy is advancing with new tumor vaccines. Research shows these vaccines are safe and effective, even for previously untreatable tumors, offering a promising new cancer treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying and reprogramming softness-driven cancer stem-like cells overcomes CAR-T cell resistance in solid tumours.

Nature biomedical engineering·2026
Same author

Bittersweet: how hyperglycemia exacerbates vitiligo progression through the succinate/SUCNR1 axis.

The Journal of clinical investigation·2026
Same author

Beyond Human Papillomavirus (HPV): Detection of EBV and Polyomaviruses in Cervical and Anal Samples.

Journal of medical virology·2026
Same author

Targeting STAT3 Promotes Tumor Cell Death and Enhances T-Cell Activity in HPV16-Positive Cancer.

Cancers·2026
Same author

NTX250: A Modular mRNA-Based Immunotherapy Platform for HPV-Associated Cancers with Broad Applicability.

bioRxiv : the preprint server for biology·2025
Same author

HPV16 E6 and E7 expressing cancer cells suppress the antitumor immune response by upregulating KLF2-mediated IL-23 expression in macrophages.

Journal for immunotherapy of cancer·2025

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Immunotherapy presents a significant advancement in human cancer treatment.
  • Progress in identifying tumor-associated antigens is crucial for developing effective cancer therapies.
  • Animal models are instrumental in translating immunological knowledge into therapeutic strategies.

Purpose of the Study:

  • To explore the potential of tumor vaccines in cancer treatment.
  • To investigate the role of tumor-associated antigens and immunogenicity in vaccine design.
  • To assess the safety and efficacy of novel dendritic cell-based vaccines.

Main Methods:

  • Analysis of tumor-associated antigens.
  • Development of tumor vaccines incorporating adjuvants to enhance immunogenicity.

Related Experiment Videos

  • Utilizing insights from dendritic cell physiology in vaccine design.
  • Conducting Phase I and II clinical trials for newly designed vaccines.

    • Main Results:

    • Several tumors previously considered non-immunogenic are now viable targets for vaccination.
    • Newly developed vaccines, incorporating dendritic cell knowledge, are progressing through clinical trials.
    • Current assessments indicate that tumor vaccines are safe for patient use.

    Conclusions:

    • Tumor vaccines represent a safe and promising therapeutic strategy for human cancer.
    • These vaccines warrant a more significant role in the comprehensive treatment of cancer.
    • Continued research into tumor immunology and vaccine development is essential for advancing cancer care.